Kisspeptin and the G protein-coupled receptor 54 (GPR54) are highly abundant in the pancreas. In addition, circulating kisspeptin directly influences insulin secretion through GPR54. However, the mechanisms by which kisspeptin affects insulin release are unclear. The LIM-homeodomain transcription factor, Isl-1, is expressed in all pancreatic islet cells and is involved in regulating both islet development and insulin secretion. We therefore investigated potential interactions between kisspeptin and Isl-1. Our results demonstrate that Isl-1 and GPR54 are coexpressed in mouse pancreatic islet ␤-cells and NIT cells. Both in vitro and in vivo results demonstrate that kisspeptin-54 (KISS-54) inhibits Isl-1 expression and insulin secretion and both the in vivo and in vitro effects of KISS-54 on insulin gene expression and secretion are abolished when an Isl-1-inducible knockout model is used. Moreover, our results demonstrate that the direct action of KISS-54 on insulin secretion is mediated by Isl-1. Our results further show that KISS-54 influences Isl-1 expression and insulin secretion through the protein kinase C-ERK1/2 pathway. Conversely, insulin has a feedback loop via the Janus kinase-phosphatidylinositol 3-kinase pathway regulating kisspeptin expression and secretion. These findings are important in understanding mechanisms of insulin secretion and metabolism in diabetes. (Molecular Endocrinology 28: 1276 -1290, 2014) 
A bnormalities in insulin secretion are closely associated with diabetes (1), an obesity-related disease that is increasing worldwide. Therefore, mechanisms regulating insulin secretion under physiological and pathological conditions have been extensively studied (2) . Insulin secretion and global insulin levels are affected by a number of factors, including extrinsic factors acting on ␤-cells, such as leptin (3, 4) , and kisspeptin (5-10) and ␤-cellintrinsic factors such as paired box transcription factor 4 (Pax4) (11), Nkx6.1 (12) , V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) (13) , Forkhead-a (14) , pancreatic duodenal homeobox-1 (Pdx1) (15, 16) , and Isl-1 (17, 18) , most of which are required for pancreatic development and maintenance of cellular function (19 -21) . Interactions between extrinsic and intrinsic factors and the molecular mechanisms modulating insulin secretion still remain to be elucidated.
The KISS-1 gene encodes a hydrophobic 145-amino acid protein that can be hydrolyzed to produce kisspeptin (KISS)-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10, which form a family of peptides called kisspeptins (22) . KISS-1 was originally discovered in breast cancer and in melanoma cell lines, and KISS-1 expression may suppress the metastatic potential of malignant melanoma cells (23) . G protein-coupled receptor 54 (GPR54), a G-protein-coupled receptor, has been identified as the receptor for kisspeptins (22, 23) . There is evidence that the hypothalamic KISS-1/GPR54 system is involved in controlling puberty onset by regulating the release of GnRH from hypothalamic neurons (24 -26) . Recent studies have shown that kisspeptin and GPR54 are highly expressed in pancreatic islet ␤-cells (9) and are involved in regulating insulin secretion (5) (6) (7) (8) (9) (10) .
The signaling pathways of kisspeptins have been investigated in different tissues. It is generally thought that kisspeptin's binding to GPR54 stimulates the G protein Gq to activate phospholipase C, which increases intracellular inositol 1, 4, 5-triphosphate, Ca 2ϩ mobilization, and arachidonic acid release and enhances the phosphorylation of ERK1/2 and p38 MAPK (22) , similar to the pathway found in hypothalamic GnRH neurons (27) . However, in human embryonic kidney 293 cells, the enhancing effect of GPR54 on ERK1/2 activity is mediated by the G protein-coupled receptor kinase-2 and ␤-arrestin-2 (28) . In mouse embryonic fibroblast cell lines, ␤-arrestin-1 inhibits the regulating effect of KISS1/GPR54 on ERK1/2 expression (29) . In the pancreatic islet, phospholipase C, ERK1/2, and intracellular Ca 2ϩ concentration [(Ca 2ϩ )(i)] take part in the intracellular signaling pathways of kisspeptin-10 (5), but key factors and molecular mechanisms by which kisspeptins influence insulin secretion require further elucidation.
The LIM-homeodomain transcription factor Isl-1 is required for pancreatic development (19) and insulin secretion (30 -32) . Isl-1 regulates hormone biosynthesis and secretion in pancreatic islet cells by interactions with transcription factors Maf (13, 33) , BETA2 (18) , cAMP response binding protein (31) , and Arx (32) . Genetic studies on morbidly obese humans suggest that Isl-1 is closely associated with type 2 diabetes (34) . However, factors affecting Isl-1 expression and its relationship to insulin secretion under physiological and pathological condition require further investigation.
The aims of the present study are to investigate whether Isl-1 mediates the effects of kisspeptin on insulin secretion and to identify interactions between kisspeptin signaling molecules and the transcription factor Isl-1. We found that kisspeptin inhibits Isl-1 expression and insulin secretion and that Isl-1 ablation significantly weakens effects of kisspeptin on insulin secretion. In addition, our findings demonstrate that Isl-1 acts downstream of kisspeptin signaling through the protein kinase C (PKC)-ERK1/2 pathway to influence insulin secretion, and that insulin has a feedback loop through the Janus kinase (JAK)-phosphatidylinositol 3-kinase (PI3K) signaling pathway that regulates kisspeptin's gene expression and secretion. These results are important in understanding mechanisms regulating insulin secretion and for finding novel targets for physiological or pharmacological interventions for diseases resulting from insulin secretion abnormalities, such as diabetes.
Materials and Methods

Animal treatments and reagents
Adult male mice (6 -8 wk) used for this study were approved by the Chinese Association for Laboratory Animal Sciences. The mice were kept in a 14-hour light, 10-hour dark cycle, with food and water provided ad libitum. The animals were killed by cervical dislocation.
Mice glucose and insulin tolerance tests were performed as previously described (35) (36) (37) , and blood glucose was measured using an Ascensia Elite glucometer (Bayer).
The collected pancreatic tissue samples were fixed in 4% paraformaldehyde in PBS (pH 7.4) for 6 hours at room temperature (RT), embedded in paraffin, and cut to 5-m sections. The pancreatic tissue for mRNA and protein analysis were immediately frozen in liquid nitrogen and preserved at Ϫ80°C.
Human KISS-54 peptide was supplied by RayBiotech (RayBiotech). We used a floxed Isl-1 allele (Isl-1 F/F ) in which loxP sites were inserted into the introns flanking exon4 of the Isl-1 locus and a tamoxifen inducible knock-in-Isl-1 mERCre-mER allele (38, 39). Isl-1 MCM/ϩ mice were interbred with Isl-1 F/F mice to produce Isl-1 MCM/F induced knockout mice (Isl-1 MCM/Del ). In Isl-1 MCM/F and Isl-1 F/ϩ mice, the mice pancreas were harvested after 5 consecutive days of injecting them with 1 mg per 10 g weight of tamoxifen as previously reported (38) . Isl-1 F/ϩ mice were used as controls.
Cell culture
NIT cells were cultured in DMEM (Gibco BRL) supplemented with 10% fetal bovine serum (Gibco BRL) and antibi- 
Radioimmunoassay
NIT cells and the pancreatic islets from inducible knockout (IKO) and control mice were incubated in DMEM containing 16.5 mM glucose and subjected to various concentrations of KISS-54 (0.1, 1, and 10 nM) for 3 hours. Each incubation vial contained 100 islets. Immediately after incubation, an aliquot of the medium was removed and frozen for subsequent insulin assays with RIA reagents provided by the Beijing North Institute Biological Technology (Beijing, China). For each RIA, the intraand interassay coefficients of variation were less than 10% and less than 15%, respectively.
Enzyme-linked immunosorbent assay
NIT cells were incubated in DMEM containing 16.5 mM glucose and subjected to 10 Ϫ8 M insulin for 12 hours. For in vivo mouse studies, insulin was administered ip to the mice at a dose of 5 IU/kg for 12 hours. The harvested medium, serum, and pancreatic tissues were frozen for subsequent assays of kisspeptin with the ELISA kit reagents (Uscn Life Science).
Islet size
Islet size was determined using Image-Pro Plus imaging software (Media Cybernetics) following the manufacturer's instructions as previously described (41) . Briefly, pancreatic tissues from four control mice and four IKO mice were used. Pancreatic tissue were fixed in 4% paraformaldehyde in PBS for 6 hours at RT and embedded in paraffin. To determine the average islet size in pancreas, consecutive sections of 5-m thickness were cut, five sections were collected at 200 m intervals from each mouse according to the previous report (42) , and all large islets (Ͼ15 ϫ 10 3 m 2 ) in each section were selected and analyzed. The tissue slices were deparaffinized in xylene and rehydrated in ethanol, and then pancreas sections were stained with hematoxylin. The sections were photographed, and areas of all selected islets and the number of these islets were determined by using Image-Pro Plus(Media Cybernetics). Finally, the average islet size was calculated by total islets area divided by number of islets.
Ca
2؉ measurement
The [Ca 2ϩ ](i) of NIT cells was measured using a spectrofluorophotometer (RF-4500; Hitachi) as described in our previous report (43) .
PCR and real-time PCR
Total RNA was extracted using the TriZol reagent kit (Vigorous Biotechnology) according to the manufacturer's recommendations. RT-PCR was performed using 2 g of total RNA reverse transcribed using a Moloney murine leukemia virus reverse transcriptase (Promega) according to the manufacturer's protocols. Isl-1, GPR54, insulin, and the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression were assayed using the primers in Table 1 .
Immunohistochemistry and immunocytochemistry
For immunohistochemistry, the pancreas sections were dewaxed, rehydrated, and treated with 10% normal goat or donkey serum in PBS to block nonspecific binding sites. For insulin, GPR54, and kisspeptin staining, we used the following antibodies: mouse antiinsulin (1:50; Santa Cruz Biotechnology), rabbit-anti-GPR54 (1:50; Abcam), rabbit-antikisspeptin (1:150; Phoenix Pharmaceuticals). The sections were then incubated with a biotinylated goat antirabbit IgG (1:200; Zymed Laborato- ries) or a biotinylated goat antimouse IgG (1:200; Zymed Laboratories) for 2 hours at RT. The sections for Isl-1 were treated with 10% normal donkey serum in PBS to block nonspecific binding sites and then incubated with goat anti Isl-1 antibody (1:50; R&D Systems) overnight at 4°C and incubated with a biotinylated donkey antigoat IgG (1:200; Sigma-Aldrich) at RT for 2 hours. Fluorescein isothiocyanate or tetraethyl rhodamine isothiocyanate-conjugated streptavidin (1:50; Southern Biotech) were used for immunofluorescence and were incubated at RT for 2 hours. Finally, the sections were counterstained with the DNA dye Hoechst33258 and/or 4Ј,6Ј-diamino-2-phenylindole.
For immunocytochemistry, the NIT cells were fixed in 4% paraformaldehyde for 20 minutes, and permeabilized with 0.2% Triton X-100 in PBS for 15 minutes at 4°C. Subsequently, the NIT cells were stained using the same protocol as above.
Western blot analysis
Western blots were performed as in our previous report (43) . For Isl-1 analysis, the membranes were incubated overnight at 4°C with goat anti-Isl-1 antibody (1:1000; R&D Systems) and mouse anti-GAPDH antibody (1:8000; mouse monoclonal). For ERK, JAK, Akt, and MafA analysis, the membranes were blocked as above and then incubated in 1:1000 diluted primary antibodies overnight at 4°C. The phosphorylated (p)-ERK1/2, p-JAK, pAKt, total ERK1/2, total JAK, and total AKt antibodies were from Cell Signaling Technology, the MafA antibody was from Sigma-Aldrich. After washing in 0.1% Tween 20-Tris-buffered saline, the membranes were incubated with the respective alkaline phosphatase-coupled antibodies (1:5000; Zymed Laboratories) for 2 hours at RT. The immunoreactive proteins were visualized using 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium (Sigma-Aldrich).
Plasmid DNA constructs
The 410-bp region of the insulin gene promoter from Ϫ1262 to Ϫ1143 bp was amplified from rat genomic DNA by PCR using specific primers ( Table 1) . The fragment was inserted into the pGL3.0 luciferase reporter vector (Promega). The expression vector for murine Isl-1 pXJ40-Myc-Isl-1 vector was kindly provided by Dr Xinmin Cao (Institute of Molecular and Cell Biology, Singapore).
Luciferase reporter assay
The Isl-1 expression vector (Addgene) was cotransfected with insulin luciferase reporter vector and pTK-Ranilla vector (Promega) into 293T cells and NIT cells. The cells were harvested 24 hours after transfection. Luciferase activity was measured using the dual-luciferase assay kit (Promega) and on a Modulus microplate luminometer (Turner Biosystems). The values shown by Firefly (Fluc) to Renilla luciferase (Rluc) activity ratio were normalized to that of an empty luciferase reporter control.
Statistical analysis
All data were analyzed using oneway factorial ANOVA, followed by a Student's t test. All values were ex- Figure 1F ) results show that both Isl-1 and GPR54 are detected in mouse pancreatic islets. These data show that GPR54, Isl-1 and insulin are coexpressed in all pancreatic islet ␤-cells but not in surrounding pancreatic exocrine glands.
Consistent with the results in the pancreas, Isl-1 and GPR54 are also expressed at significant levels in all NIT cells (Figure 1, C-F ). In addition, most NIT cells contain insulin ( Figure 1C ), in agreement with a previous report (44) . These results suggest that NIT cells could be used as an in vitro cell model to investigate potential molecular cross talk between KISS-54 and Isl-1 for insulin secretion regulation.
KISS-54 suppresses Isl-1 expression and insulin secretion in NIT cells
To investigate a potential functional relationship between KISS-54 and Isl-1 in regulating insulin synthesis and secretion, we assessed the effects of KISS-54 on Isl-1 expression and insulin secretion in NIT cells, which were incubated in DMEM with 16.5 mM glucose. Cultured NIT cells were treated with 0.1, 1, or 10 nM KISS-54 for 3 hours according to the previous reports (6, (45) (46) (47) (48) , and cellular Isl-1 and insulin mRNA levels as well as insulin levels in the culture medium were analyzed. Results demonstrate that KISS-54 treatment causes a sharp decrease in Isl-1 and insulin gene expression (Figure 2A , P Ͻ .01) and reduced insulin secretion ( Figure 2B , P Ͻ .05).
To check whether the effects of KISS-54 on Isl-1 expression and insulin secretion are dependent on the duration of KISS-54 treatment, we measured insulin secretion and gene expression of Isl-1 and insulin after incubating NIT cells with 10 nM KISS-54 for 0.5, 1, or 3 hours. Results demonstrate that 0.5, 1, and 3 hours of treatment with KISS-54 significantly decreases Isl-1 and insulin gene expression ( Figure 2C , P Ͻ .01), but there is no obvious time dependence of the effects of KISS-54 treatment. Similar effects on Isl-1 protein levels were detected by Western blot, and the effects on insulin secretion were detected by RIA (Figure 2 , D and G, P Ͻ .01).
To investigate whether KISS-54 has a role in regulating insulin degradation, we tested the effect of KISS-54 treatment on insulin degradation according to the previous reports (49 -51) , and the results showed that KISS-54 treatment has no obvious effect on insulin degradation in different time points ( Figure 2E ). In addition, we analyzed the effects of KISS-54 on the mRNA expression of islet transcription factors MafA, Pdx1, Pax4, Nkx6.1, and neurogenin 3 (Ngn3) in NIT cells after 3 hours of treatment with 10 nM KISS-54. Results demonstrate that KISS-54 treatment has no significant effect on mRNA levels of these factors, with the exception of MafA mRNA levels, which significantly increased ( Figure 2F , P Ͻ .05).
KISS-54 suppresses Isl-1 expression and insulin secretion in the pancreas
To determine whether KISS-54 has similar physiological effects on Figure 3 . Effects of KISS-54 on Isl-1 expression and insulin secretion in the pancreas. A, Relative mRNA levels of Isl-1 and insulin by RT-PCR in mouse pancreas after injection with 10 nM KISS-54 via caudal vein injection at 0 hours (control), NaCl (no leptin), 0.5, 3, and 6 hours. B, Isl-1 protein levels in the mouse pancreas injected with 10 nM KISS-54 harvested at distinct time points after injection and detected by Western blot (GAPDH was used as a loading control). C, Insulin levels in the mouse pancreas injected with 10 nM KISS-54 and harvested at distinct time points after injection as measured by RIA. Data are shown as means Ϯ SD from three samples for each group. Significant differences are indicated by *, P Ͻ .05 and **, P Ͻ .01.
Isl-1 expression and insulin secretion in vivo, we administered 10 nM of KISS-54 in 200 L 0.9% NaCl to mice via a caudal vein injection. Pancreatic Isl-1 mRNA and protein levels were examined at 0.5, 3, and 6 hours, respectively. Results show that KISS-54 significantly decreases pancreatic Isl-1 and insulin mRNA levels at 0.5 hours, compared with the control, which persisted until 6 hours ( Figure 3A , P Ͻ .01). However, pancreatic Isl-1 protein levels and serum insulin levels significantly decline at 3 hours and persist until 6 hours ( Figure 3 , B and C).
Isl-1 is efficiently knocked down in the Isl-1-inducible knockout mice
To confirm whether the effects of KISS-54 on insulin secretion are Isl-1 dependent, we used Isl-1 MCM/F IKO mice. Isl-1 F/ϩ mice were used as controls. The strategy Figure  4A , P Ͻ .01). Similar to the changes in Isl-1 gene expression, Isl-1 protein levels in pancreatic islets of IKO mice are significantly lower than those in controls as seen by the Western blot ( Figure 4B ). Immunofluorescence results (Figure 4, C and D) demonstrate that the percentage of Isl-1 positive cells is significantly lower in the pancreas of IKO mice than in the controls. These findings are similar to our recent report (52) . In addition, there are no evident size differences between the number of islets per pancreas between the control and IKO mice ( Figure 4E ). These data demonstrate the efficient Cre mediated deletion of Isl-1 in vivo.
Effects of Isl-1 deletion on glucose and insulin tolerance tests
To evaluate effects of Isl-1 deletion on the general metabolisms of the mouse, we compared blood glucose and plasma insulin levels between IKO and control mice in fasting and fed conditions. Results show that Isl-1 IKO mice display higher blood glucose levels ( Figure 5A ) and lower plasma insulin levels as compared with control mice in both fasting and regularly fed conditions ( Figure  5B , P Ͻ .05).
In addition, we evaluated islet function by ip glucose and insulin tolerance tests. Isl-1 IKO mice display profound glucose and insulin tolerance impairment ( Figure 5 , C and D, P Ͻ .01). In vivo glucose-stimulated insulin secretion was markedly depressed in Isl-1 IKO mice compared with control mice (Figure 5E , P Ͻ .01), potentially explaining their impaired glucose tolerance.
Effects of KISS-54 on insulin gene expression and secretion in IKO mice and isolated islets of IKO mice
Because a numbers of factors, including MafA, Pdx1, Pax4, Nkx6.1, and Ngn3, are involved in regulation of insulin gene expression and islet function, we examined the effects of the Isl-1 deletion expression of these genes. Real-time PCR results show that Isl-1 deletion significantly decreases MafA mRNA and protein levels but does not significantly change the gene expression of the other transcription factors ( Figure 6 , A and B, P Ͻ .05).
To investigate whether Isl-1 mediates the effects of KISS-54 on insulin expression and secretion, 10 nM KISS-54 was administered to IKO and control mice via a caudal vein injection. After 6 hours, KISS-54 treatment resulted in a 49.75% decline in insulin mRNA and a 45.3% decline in serum insulin levels in control mice. However, KISS-54 treatment had no significant effect on insulin mRNA and serum insulin levels in IKO mice ( Figure 6 , C and D, P Ͻ .05). These findings demonstrate that the in vivo inhibition of insulin secretion by KISS-54 is at least partly mediated by Isl-1. We isolated pancreatic islets from IKO and control mice ( Figure 6E ) as previously described (40) and also deleted Isl-1 in floxed mice by 4-OHT-induced Cre expression for 48 hours before the collection of pancreatic islets as previously reported (53). Isl-1 gene expression in islets from IKO mice and control mice was detected by RT-PCR. Results show that the expression levels of Isl-1 exons 3/4 decreased by 67.5% in IKO mice compared with the control levels ( Figure 6F , P Ͻ .01). These findings are in agreement with our recent Figure 5 . Glucose homoeostasis in Isl-1 IKO and control mice. A, Blood glucose levels in IKO and control mice. B, Plasma insulin levels in IKO and control mice. C, Blood glucose levels before and after ip injection of glucose in IKO and control mice. D, Blood glucose levels before and after ip injection of insulin in IKO and control mice. E, Plasma insulin levels before and after ip injection of glucose in IKO and control mice at specific time points after injection. Data are shown as means Ϯ SD from three samples for each group. Significant differences are indicated by *, P Ͻ .05 and **, P Ͻ .01 (n ϭ 6).
report (52) . These results indicate efficient Cre Isl-1 excision in isolated islets of Isl-1 MCM/F mice.
To identify whether the effects of KISS-54 treatment on insulin secretion are mediated by Isl-1 in isolated islets, 10 nM KISS-54 was added to 4-OHT-treated islets. Results demonstrate that KISS-54 treatment decreases insulin levels by 46.7% after 3 hours of treatment in control islets, but no significant effect of KISS-54 treatment on insulin secretion in IKO islets is seen ( Figure 6G , P Ͻ .05). . Effects of KISS-54 on insulin gene expression and secretion in IKO mice and isolated islets. A, Real-time PCR analysis of mRNA levels of islet transcription factors in IKO and control mice. B, Western blot of MafA and GAPDH protein levels in IKO and control mice. C, Insulin mRNA levels measured by real-time PCR in mice treated with 10 nM KISS-54 via caudal vein injection at 0 hours (control), NaCl (no KISS-54), and 6 hours. D, Serum insulin levels measured by RIA in mice treated with 10 nM KISS-54 via caudal vein injection. E, Preparation of isolated pancreatic islets was performed by retrograde injection of a collagenase solution via the bile-pancreatic duct. F, RT-PCR primers targeting exon 1, exon 3/4, and exon 6 were used to assay Isl-1 mRNA in isolated pancreatic islets from IKO and control mice. G, RIA detected insulin levels in media from isolated islets of IKO and control mice treated with 10 nM KISS-54. Data are shown as means Ϯ SD from three samples for each group. Significant differences are indicated by *, P Ͻ .05) and **, P Ͻ .01. Bars, 30 m. Chelerythrine chloride, the ERK1/2 antagonist PD98059, the P38 inhibitor SB203580, the JAK-selective tyrosine kinase inhibitor AG490, or the signal transducer and activator of transcription 3 (STAT3) phosphorylation suppressor Parthenolide for 1 hour before the addition of KISS-54 for 6 hours. The inhibition of Isl-1 mRNA and protein expression (Figure 7 , A and C, P Ͻ .05) and insulin secretion ( Figure 7B , P Ͻ .05) by KISS-54 were blocked by both CH and PD98059. Cultured cells were then exposed to 10 nM KISS-54 for up to 60 minutes and phosphorylated ERK1/2 was analyzed by Western blot. Results show that KISS-54 treatment significantly increases phosphorylated ERK1/2 levels after 5 minutes exposure ( Figure 7D , P Ͻ .05 ](i) was detected using the Fura-2 method. Results show that KISS-54 induces an increase in intracellular calcium levels within about 10 seconds, which persists until 140 seconds ( Figure 7E ).
Isl-1 increases insulin promoter activity in 293T and NIT cells
To determine whether Isl-1 is involved in regulating insulin gene transcription, pXJ40-Myc-Isl-1 (54) was transfected into 293T cells and NIT cells with insulin promoter-luciferase vectors. Results from a dualluciferase reporter assay show that Isl-1 enhances the activities of Ϫ410-insulin about 20.4-fold in 293T cells ( Figure 8A , P Ͻ .01) and 3.9-fold in NIT cells ( Figure 8B , P Ͻ .01). In contrast, Isl-1 overexpression did not change the luciferase activity of a pGL3.0-basic control vector. These results are in agreement with a previous report (18) that Isl-1 influences insulin levels through enhancing insulin promoter activity. 
Insulin has feedback effects on kisspeptin expression and secretion through JAK and PI3K signaling pathways
Because pancreatic islet cells function to secrete kisspeptin, we wanted to identify whether insulin has a feedback loop regulating KISS-1 gene expression and kisspeptin secretion. We cultured NIT cells with 10 Ϫ8 M insulin in DMEM and with 16.5 mM glucose for 12 hours. Results show that insulin significantly decreases KISS-1 mRNA levels in NIT cells and kisspeptin concentration in the medium, as detected by RT-PCR and ELISA, respectively ( Figure 9 , A and B, P Ͻ .05). Next, we administered insulin ip to mice at a dose of 5 IU/kg for 12 hours. KISS-1 mRNA levels in pancreas and kisspeptin concentrations in pancreatic tissue and serum were assessed. RT-PCR results show that insulin decreases KISS-1 mRNA levels. The ELISA results show that insulin significantly decreases kisspeptin concentration in pancreatic tissue (Figure 9 , C and D, P Ͻ .05),but has no effect on serum concentrations of kisspeptin.
To determine signaling pathways downstream of insulin, which affects kisspeptin expression and secretion, we initially assessed the effects of insulin on insulin receptor gene expression in NIT cells and in the pancreas. Results confirm that insulin treatment down-regulates insulin receptor gene expressions in vitro and in vivo. To identify the signaling pathways downstream of insulin and its receptors that influence kisspeptin expression and secretion, the PKC inhibitor CH, ERK1/2 antagonist PD98059, JAK-selective tyrosine kinase inhibitor AG490, STAT3 phosphorylation suppressor Parthenolide, or PI3K inhibitor 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride (LY) were added to cultured NIT cells before treatment with insulin as above. RT-PCR results show that both AG490 and LY treatments block insulin inhibition of KISS-1 gene expression and kisspeptin secretion ( Figure 9 , E and F).
We confirmed that LY treatment blocks the effects of insulin on kisspeptin expression by immunofluorescence in NIT cells. LY was added to cultured NIT cells before treatment with insulin as above. Results show that decreased kisspeptin expression in NIT cells, as evidenced by decreased immunofluorescence staining for kisspeptin after treatment with insulin, is blocked after exposure to LY ( Figure 10A ). We then treated NIT cells with 10 Ϫ8 M insulin for 0, 5, 10, 20, and 50 minutes. Phosphorylated JAK and phosphorylated AKt were analyzed by Western blot. Results show that insulin significantly increases JAK phosphorylation after a 5-minute exposure, and this effect persists until 50 minutes ( Figure  10B , P Ͻ .05). At the same time, insulin treatment significantly increases phosphorylated AKt protein levels after a 20-minute exposure, and this effect persists until 50 minutes ( Figure 10C , P Ͻ .01). These findings indicate that the downstream signaling pathway by which insulin and its receptor affect the kisspeptin synthesis and secretion uses JAK and PI3K but not PKC or ERK1/2.
Discussion
The regulating effects of the kisspeptins (5-9) and Isl-1 (30) on insulin secretion in the pancreas have been previously reported. However, a functional relationship between kisspeptins and Isl-1 has not been established for regulating insulin secretion. Our results demonstrate that Isl-1 and GPR54 are highly expressed in mouse pancreatic islet ␤-cells and NIT cells, and nearly all of the insulinpositive cells in the pancreas and NIT cells coexpress Isl-1 and GPR54. In addition, our functional experiments have demonstrated that exogenously added KISS-54 significantly inhibits mRNA expression of Isl-1 and insulin in the mouse pancreas and in cultured NIT cells. In addition, KISS-54 treatment significantly decreases global insulin levels and insulin secretion in NIT cells. However, KISS-54 treatment has no obvious effect on insulin degradation in different time points, and these results infer that KISS-54 may be through other manners to decrease insulin level rather than affect insulin degradation. Previous observations indicated that substantial amounts of insulin were degraded intracellularly in isolated pancre- mend.endojournals.orgatic islets exposed to low glucose concentrations (55) . Inversely, there was no insulin degradation in islets incubated at a high glucose concentration according to the previous report (56) . The glucose concentration in our study belonged to high glucose concentration, the islet cells of this culture system was not easy to produce insulin degradation for outside stimulation. This supports the original results that KISS-54 reduced insulin level by inhibiting Isl-1 expression. In addition, some Isl-1 target genes that regulate insulin synthesis or/and secretion may be involved in the process according to the previous report (17) . The interactions or cross talk among those signaling pathways and the related mechanisms are still waiting for further studies.
In the present study, we used an Isl-1 IKO mouse model to assess whether KISS-54's effect on insulin secretion is dependent on Isl-1. We used a conditional ablation strategy using a tamoxifen-inducible mER-Cre-mER recombinase cassette targeted to the Isl-1 locus (Isl-1 MCM/F ). First, we examined Isl-1 deletion efficiency in this model and demonstrated efficient ablation of Isl-1 in the pancreas and in cultured pancreatic islets (39) . Furthermore, we compared blood glucose, plasma insulin levels, and glucose homeostasis between IKO and control mice. Ablation of Isl-1 results in impairment but not in complete loss of glucose and insulin tolerance. To better understand the pathophysiological basis of impaired glucose tolerance in Isl-1 IKO mice, we studied glucose-stimulated insulin secretion in pancreas, and the results show that the insulin secretion response to glucose was reduced in Isl-1 IKO mice compared with control mice. At the same time, Isl-1 deficiency decreases insulin gene transcription and thus reduces insulin output in IKO mice. These collective results are in agreement with a previous report (30) , although our inducible knockout efficiency was lower than the efficiency of conditional knockouts in that report.
Isl-1's involvement in insulin secretion is also supported by in vitro experiments showing that KISS-54 treatment does not have a significant effect on cultured pancreatic islet cells from IKO mice. In addition, the effects of KISS-54 on insulin gene expression and secretion are inhibited in IKO mice. These results suggest that Isl-1 is critical for mediating KISS-54's effects on insulin secretion and that Isl-1 affects the promoter activity of the insulin gene, a finding supported by a previous report (18) . The effect of Isl-1 on insulin secretion is a complex regulatory process, and Isl-1 may indirectly affect insulin secretion by regulating other hormones, such as somatostatin. Isl-1 requires the cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells (31) , and somatostatin regulates insulin secretion by different signaling pathways (57) (58) (59) (60) . Insulin infused at a different concentration produce different effects on somatostatin secretion (61) . These studies sup- ports the notion of a negative feedback relationship between ␤-and ␦-cells of the pancreatic islets, and under physiological circumstances their respective actions are inseparable. The specific mechanism still need to be further investigated.
Because different KISS-1/GPR54 signaling pathways have been proposed in different tissues (5, (27) (28) (29) , we explored the downstream pathways of KISS-1/GPR54 signaling in NIT cells. There are reports that p38 MAPK and G protein-coupled receptor kinase-2, respectively, are involved in KISS-1/GPR54 signaling in the hypothalamus (22) and in human breast cancer cells (28) . Phospholipase C, ERK1/2, and [Ca 2ϩ ](i) take part in intracellular signaling pathways downstream of kisspeptin-10 in pancreatic islets (5) . These studies suggest that KISS-1/GPR54 signaling is specifically and differentially regulated in different target tissues or cells. For determining the signaling pathway of KISS-54 effect on Isl-1 expression and insulin secretion, we used specific inhibitors of PKC, protein kinase A, p38 MAPK, or ERK1/2 to see which inhibitor blocks the effects of KISS-1/GPR54 on Isl-1 expression and insulin secretion. Only the PKC inhibitor CH and the ERK1/2 inhibitor PD98059 blocked KISS-54 inhibition of Isl-1 expression and insulin secretion. We found that KISS-54 treatment significantly increases phosphorylated ERK1/2 levels after a 5-minute exposure, and KISS-54 also induces an increase in [Ca 2ϩ ](i). These results suggest that KISS-54 inhibits Isl-1 expression and insulin secretion through Ca 2ϩ -PKC-ERK1/2 pathways. However, calcium was a known secretagogue for insulin in some cases in pancreatic islets (5) , and the report and our results appear to be inconsistent. There are reports that the activated [Ca 2ϩ ](i) may play an opposite effect on the different conditions (62, 63) . Under physiological conditions, the magnitude of change in [Ca 2ϩ ](i) may not parallel the level of insulin release, suggesting that the role of [Ca 2ϩ ](i) in the process of insulin release must be considered in concert with other cellular mechanisms (64) . In our study, the effect of KISS-54 on insulin secretion was involved with the PKC-ERK signaling pathways and transcription factor Isl-1. In addition, the Isl-1 promoter did not contain the recognition site of ERK, and there may be other factors involved in the regulation of ERK on Isl-1. Further work is required to explore the factors responsible for differences between the observed effects in different conditions. Some studies have shown that circulating kisspeptin comes from the central nervous system (65) and plays important roles in regulating insulin secretion. There are also reports that the pancreas produces kisspeptin (8, 22) and that insulin, in turn, acts as an autocrine/ paracrine molecule to balance pancreatic hormone secretion (66, 67) . Results presented here show that Isl-1 mediates the effects of kisspeptin signaling on insulin secretion. To assess whether there is a feedback loop regulating insulin's effect on kisspeptin secretion by pancreatic islets, we investigated changes in kisspeptin gene expression and its concentration after insulin mend.endojournals.orgtreatment both in vivo and in vitro. Results confirm our hypothesis that insulin negatively regulates kisspeptin production and secretion in pancreatic islet cells. These interactions are affected by physiological or pathological criteria, such as global insulin, kisspeptin, and glucose levels. Further studies are required to fully understand interactions among kisspeptin, insulin, and related hormones within the pancreatic islet milieu. Insulin and its receptor signaling pathways have been extensively studied and multiple signaling pathways have been proposed (68, 69) . This is due to the multiple roles that insulin plays in its target tissues and cells. To identify the signaling pathway by which insulin affects kisspeptin secretion in pancreatic islets, specific inhibitors of PKC, MAPK, JAK, STAT3, or PI3K were used. Only the JAK inhibitor AG490 and the PI3K inhibitor LY blocked the effects of insulin on kisspeptin gene expression and secretion. In addition, insulin also significantly increases phosphorylated JAK and AKt protein levels at different time after insulin exposure. These findings suggest that insulin regulates kisspeptin secretion through JAK and PI3K-AKt signaling pathways, although the mechanism's details need to be further elucidated.
In conclusion, data presented here demonstrate a unique interaction between KISS-54 signaling and the transcriptional factor Isl-1. This cross talk appears to regulate the effects of KISS-54 on insulin secretion. In a negative feedback loop, insulin also inhibited KISS-54 production in pancreatic islet cells. Although actions of kisspeptin and insulin in pancreatic islet ␤-cells are accomplished through different signaling pathways (Figure 11 ), Isl-1 mediates the actions of both kisspeptin and insulin ( Figure 11 ). These results are crucial for understanding the mechanisms regulating insulin secretion and are also very important for identifying novel targets for physiological or pharmacological intervention in diseases resulting from abnormal insulin secretion, such as type 2 diabetes. Figure 11 . A model of Isl-1-mediated effects of kisspeptin on insulin synthesis and secretion. KISS-54 binds to GPR54 and activates its G-protein, which subsequently enhances phospholipase C (PLC) activation. Under PLC's effect, phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis occurs to produce diacylglycerol (DAG) and inositol 1, 4, 5-triphosphate (IP 3 ), increasing intracellular Ca 2ϩ levels. Subsequently, DAG-sensitive isoforms of PKC are activated, and phosphorylated PKC causes a downstream MAPK cascade reaction. Activated ERK1/2 affects Isl-1 mRNA and protein levels, and Isl-1 protein binds to the insulin promoter and enhances its activity to influence insulin synthesis and secretion. Extracellular insulin binds to its receptor and inhibits KISS-1 mRNA expression and kisspeptin secretion through JAK and PI3K-AKt signaling pathways. Extracellularly secreted kisspeptin is then hydrolyzed to produce KISS-54.
